BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37489148)

  • 1. Impact of Early Natural Killer Cell Reconstitution on the Outcomes of T Cell-Replete Allogeneic Hematopoietic Stem Cell Transplantation.
    Zhou Z; Liu X; Zhang X; Wen S; Hua H; Wang Z; Xu Z; Lu Y; Wang F
    J Inflamm Res; 2023; 16():2993-3008. PubMed ID: 37489148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher Dose of CD34
    Zhao F; Shi Y; Chen X; Zhang R; Pang A; Zhai W; Yang D; He Y; Feng S; Zhang P; Jiang E; Han M
    Transplant Cell Ther; 2022 Sep; 28(9):589.e1-589.e10. PubMed ID: 35714907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
    Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Natural Killer Cell Reconstitution Predicts Overall Survival in T Cell-Replete Allogeneic Hematopoietic Stem Cell Transplantation.
    Minculescu L; Marquart HV; Friis LS; Petersen SL; Schiødt I; Ryder LP; Andersen NS; Sengeloev H
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2187-2193. PubMed ID: 27664326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
    Sheng L; Mu Q; Wu X; Yang S; Zhu H; Wang J; Lai Y; Wu H; Sun Y; Hu Y; Fu H; Wang Y; Xu K; Sun Y; Zhang Y; Zhang P; Zhou M; Lai B; Xu Z; Gao M; Zhang Y; Ouyang G
    Front Immunol; 2020; 11():1534. PubMed ID: 32849519
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of Cytomegalovirus Reactivation and Natural Killer Reconstitution on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Analysis.
    Ando T; Suzuki T; Ishiyama Y; Koyama S; Tachibana T; Tanaka M; Kanamori H; Nakajima H
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):171-177. PubMed ID: 31563574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
    Mushtaq MU; Shahzad M; Shah AY; Chaudhary SG; Zafar MU; Anwar I; Neupane K; Khalid A; Ahmed N; Bansal R; Balusu R; Singh AK; Abhyankar SH; Callander NS; Hematti P; McGuirk JP
    Front Immunol; 2022; 13():1005031. PubMed ID: 36263054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Infections and Delayed CD4
    Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
    Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
    Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
    Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early T-cell reconstitution predicts risk of EBV reactivation after allogeneic hematopoietic stem cell transplantation.
    Huang J; Pan Z; Wang L; Zhang Z; Huang J; Jiang C; Cai G; Yin T
    Clin Exp Med; 2024 Jan; 24(1):22. PubMed ID: 38280072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.
    Li T; Luo C; Zhang J; Wei L; Sun W; Xie Q; Liu Y; Zhao Y; Xu S; Wang L
    Stem Cell Res Ther; 2021 Apr; 12(1):246. PubMed ID: 33879242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of early natural killer cell adoptive infusion before engraftment in protecting against human herpesvirus-6B encephalitis after naïve T-cell-depleted allogeneic stem cell transplantation.
    Gasior M; Ferreras C; de Paz R; Bueno D; Mozo Y; Sisinni L; Canizales JT; González B; Olivas-Mazón R; Marcos A; Romero AB; Constanzo A; Mirones I; Fernández-Arroyo A; Balas A; Vicario JL; Escudero A; Yuste VJ; Pérez-Martínez A
    Transfusion; 2021 May; 61(5):1505-1517. PubMed ID: 33713461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
    Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H
    Front Immunol; 2019; 10():1997. PubMed ID: 31507601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy.
    de Witte MA; Sarhan D; Davis Z; Felices M; Vallera DA; Hinderlie P; Curtsinger J; Cooley S; Wagner J; Kuball J; Miller JS
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1152-1162. PubMed ID: 29505821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT.
    Fan ZY; Han TT; Zuo W; Zhao XS; Chang YJ; Lv M; Mo XD; Sun YQ; Zhang YY; Wang Y; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XY
    Clin Exp Immunol; 2022 Jun; 208(3):332-339. PubMed ID: 35551362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing lymphocyte reconstitution after allogeneic hematopoietic stem cell transplantation in children.
    Bae KW; Kim BE; Koh KN; Im HJ; Seo JJ
    Korean J Hematol; 2012 Mar; 47(1):44-52. PubMed ID: 22479277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of different doses of antithymocyte globulin conditioning on immune reconstitution upon hematopoietic stem cell transplantation.
    Li Y; Wang M; Fang X; Jiang Y; Sui X; Li Y; Liu X; Wang X; Lu D; Sun X; Xu H; Wang X
    Transpl Immunol; 2021 Dec; 69():101486. PubMed ID: 34678462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Relapse-Free Survival in Patients With High Natural Killer Cell Doses in Grafts and During Early Immune Reconstitution After Allogeneic Stem Cell Transplantation.
    Minculescu L; Fischer-Nielsen A; Haastrup E; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Sengelov H; Marquart HV
    Front Immunol; 2020; 11():1068. PubMed ID: 32547559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.